ALULA HAILE: Open Payments
NPI 1881424059 · IRVINE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,988 in 80 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $1,446 · 2025 $1,988
Food & beverage: $1,988
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $319 |
| Vanda Pharmaceuticals Inc. | 8 | $281 |
| Otsuka America Pharmaceutical, Inc. | 7 | $157 |
| Janssen Pharmaceuticals, Inc | 6 | $146 |
| Axsome Therapeutics, Inc. | 5 | $146 |
| ABBVIE INC. | 10 | $144 |
| Alkermes, Inc. | 4 | $123 |
| Lundbeck LLC | 5 | $110 |
| Teva Pharmaceuticals USA, Inc. | 5 | $110 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $95 |
Products named: INGREZZA, FANAPT, REXULTI, VRAYLAR, ARISTADA, CAPLYTA, ABILIFY ASIMTUFII, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
